Amphastar P is a drug manufacturers - specialty & generic business based in the US. Amphastar P shares (AMPH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $36.63 – an increase of 0.91% over the previous week. Amphastar P employs 1,761 staff and has a trailing 12-month revenue of around $723.5 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $36.63 |
|---|---|
| 52-week range | $34.69 - $56.88 |
| 50-day moving average | $43.96 |
| 200-day moving average | $43.54 |
| Wall St. target price | $56.40 |
| PE ratio | 12.1694 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $3.01 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $36.63 from 2025-01-08
| 1 week (2025-01-03) | 0.91% |
|---|---|
| 1 month (2024-12-10) | -16.06% |
| 3 months (2024-10-10) | -20.87% |
| 6 months (2024-07-10) | -2.01% |
| 1 year (2024-01-10) | -33.18% |
|---|---|
| 2 years (2023-01-10) | 30.36% |
| 3 years (2022-01-10) | 41.81% |
| 5 years (2020-01-10) | 96.30% |
Valuing Amphastar P stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amphastar P's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amphastar P's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Amphastar P shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Amphastar P's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.77. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amphastar P's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amphastar P's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $266.6 million.
The EBITDA is a measure of a Amphastar P's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $723.5 million |
|---|---|
| Operating margin TTM | 29.83% |
| Gross profit TTM | $248.9 million |
| Return on assets TTM | 8.67% |
| Return on equity TTM | 23.85% |
| Profit margin | 21.8% |
| Book value | $15.04 |
| Market Capitalization | $1.8 billion |
TTM: trailing 12 months
We're not expecting Amphastar P to pay a dividend over the next 12 months.
Over the last 12 months, Amphastar P's shares have ranged in value from as little as $34.69 up to $56.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amphastar P's is 0.824. This would suggest that Amphastar P's shares are less volatile than average (for this exchange).
Amphastar Pharmaceuticals, Inc. , a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Access remote advice, planning and portfolio management from this established financial services company.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.